The results showed clear differences between people with chronic back pain and those without pain. On average, people with ...

Are apps like this one an important part of the future of chronic pain care? Those living with chronic pain see potential, ...

Mercy Family Health and Pain Management opens DuBois, PA clinic offering StemWave Therapy, an FDA-cleared non-surgical ...

In severe cases, opioids are sometimes used, but these drugs can lead to addiction, overdose, and other serious risks. For this reason, doctors and scientists have been searching for safer ways to ...

Chronic pain might quietly push people toward developing high blood pressure—and the more widespread the pain, the greater the danger. A massive analysis of over 200,000 adults uncovered strong links ...

Lexicon Pharmaceuticals (NASDAQ:LXRX) outlined progress across three late-stage programs and reported sharply lower operating ...

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering ...

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q4 2025 Earnings Call Transcript March 5, 2026 Lexicon Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.04, expectations were $-0.07.

("DIMERx" or "the Company"), is a clinical-stage biopharmaceutical company dedicated to addressing the public-health crisis of drug abuse and dependence, with a portfolio of first-in-class, ...

Guidance for 2026 operating expenses was narrowed to $100–110 million, from $105–115 million previously. R&D expense expectations shifted lower, while SG&A guidance increased slightly. The company ...

DIMERx, Inc. ("DIMERx" or "the Company"), is a clinical-stage biopharmaceutical company dedicated to addressing the public-health crisis ...

Thanks to a new National Institutes of Health grant, a UCF College of Medicine scientist is investigating a new approach to treat neuropathy without relying on pain pills and anti-depressants.